Transgene and NEC join forces to advance personalized cancer vaccine

TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor

Regeneron and TriNetX forge $200M partnership to supercharge drug discovery and digital health

TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners

WHO updates global guidelines to combat opioid crisis

Opioid dependence remains a major driver of death and disease worldwide

OneCyte and Kemp Proteins to revolutionize cell line development

Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules

Moderna to reveal late-breaking data on flu & RSV mRNA vax at ESCMID 2026

The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21

KIMS Hospitals launches cutting-edge Neurosciences Institute in Mahadevapura

Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9 billion

The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio

Stipple Bio raises $100M Series A to advance next-gen cancer therapies

The new capital is expected to fund the company through 2029

Biocon launches denosumab biosimilars Bosaya and Aukelso in US market

Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market

Lupin wins USFDA nod for generic Dapagliflozin tablets

Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market